Why Quorum: The Quorum Difference | Quorum Review IRB


About Quorum

Quorum Review IRB, the first name in streamlined, service-centered independent ethics and regulatory review, assures the ethical integrity of clinical research. With our partners, we advance the frontiers of medical innovation while sustaining the rights, dignity, and safety of participants.

The Quorum difference is One-Touch Collaboration™. Your research benefits from an outstanding service experience, a single point of contact, one study startup timeline, and a true single board review—which is why Quorum is the preferred central IRB.

> Start Your Study

As the largest privately held IRB, we have the resources and experience to help you navigate the ethical, legal and regulatory risks associated with complex, far reaching clinical studies, paired with the agility required to meet your study’s unique needs.


Explore Our Full Range of Services

We are the only IRB to offer harmonized IRB and IBC review, API integrations, and consulting services that move your research forward. In addition to traditional IRB services, Quorum offers single IRB (sIRB) review for institutions. The consulting and technology division of Quorum, Kinetiq, offers tailored solutions that enhance and optimize your clinical research operations, including on-demand regulatory consulting and an HRPP Health Check.

Start Your Study With Quorum

Our accredited ethics boards meet every day, with oversight of research in the United States, Canada, and anywhere else in the world. Submit your research today.

Get Started

Get a Quick Quote and Save Time

Quorum helps clients achieve reduced fulfillment time with free services like this. Get a no-obligation quote and budget for your next study by the next day.

Launch Your Study


Reviews of all types of submissions every day, for faster decisions


Convenient electronic tools and dedicated staff for easy, efficient study administration


A single point of contact throughout your study


Early engagement proven to save time and money in later phase trials.